Aktie A2PSV2 TETRAPHASE PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Tetraphase Pharmaceuticals, Inc.

Aktien

A2PSV2

US88165N2045

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Tetraphase Pharmaceuticals, Inc. Enters into A Termination of Lease and Voluntary Surrender of Premises Agreement
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020
La Jolla Pharmaceutical Completes Merger with Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc. Announces Executive Changes
Tetraphase Pharmaceuticals, Inc. Announces Resignation of Larry Edwards as CEO
Tetraphase Pharmaceuticals, Inc. Announces Appointment of Michael Hearne as Chief Financial Officer
Tetraphase Pharmaceuticals, Inc.(NasdaqGS:TTPH) dropped from S&P TMI Index
La Jolla Pharmaceutical Company completed the acquisition of Tetraphase Pharmaceuticals, Inc..
Armistice Capital Enters into Support Agreement with La Jolla Pharmaceutical
Tetraphase Pharmaceuticals, Inc.(NasdaqGS:TTPH) dropped from Russell Microcap Value Index
Tetraphase Pharmaceuticals, Inc.(NasdaqGS:TTPH) dropped from Russell Microcap Index
La Jolla Pharmaceutical Company : to Acquire Tetraphase Pharmaceuticals, Inc
TETRAPHASE PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
Tetraphase Pharmaceuticals : La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
Melinta Therapeutics, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..
La Jolla Pharmaceutical Sends Letter to Tetraphase Pharmaceuticals
TETRAPHASE PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form 8-K)
Tetraphase Pharmaceuticals : Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta
TETRAPHASE PHARMACEUTICALS INC : Other Events (form 8-K)
United States Food and Drug Administration Approves XERAVA of Tetraphase Pharmaceuticals, Inc
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PSV2 Aktie
  4. Nachrichten Tetraphase Pharmaceuticals, Inc.
  5. Andere Sprachen